AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1323545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 1323545 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (PPA) in extended phase
Number of subjects: 101
Study 1323545 — intervention group
Group type: COMPARATOR
Intervention: Placebo in extended phase
Number of subjects: 101
Study 364616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (75 mg daily orally and 100 mg suppository at night)
Number of subjects: 50
Study 364616 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (same dosage as ketoprofen)
Number of subjects: 50
Study 31952456 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for ultrasound features
Number of subjects: 100
Study 31952456 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for US classification systems
Number of subjects: 100
Study 31952456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer agreement for nodule US features
Number of subjects: 100
Study 31952456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer agreement for US classification systems
Number of subjects: 100
Study 30910144 — intervention group
Group type: EXPERIMENTAL
Intervention: Eryngo (5 ml syrup, 3 times a day for 5 days)
Number of subjects: 169
Study 30910144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (200 mg, 3 times a day for 5 days)
Number of subjects: 169
Study 30910144 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 ml syrup, 3 times a day for 5 days)
Number of subjects: 169
Study 29085773 — intervention group
Group type: EXPERIMENTAL
Intervention: verum iTBS
Number of subjects: 44
Study 29085773 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 44
Study 29085773 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT (both groups)
Number of subjects: 44
Study 26051570 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (PRO)
Number of subjects: 46
Study 26051570 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 46
Study 23641782 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative neuromuscular training program (8-24 training sessions plus 3 educational sessions)
Number of subjects: 80
Study 23641782 — intervention group
Group type: COMPARATOR
Intervention: Attention control program (3 educational sessions only)
Number of subjects: 80
Study 16459218 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous, multi‐media, interactive, case‐based, online CME program (minimum of 4 hours)
Number of subjects: 52
Study 16459218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CME)
Number of subjects: 52
Study 15253848 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (5 weeks, 10 sessions, 10-15 needle insertions per session, needles left in situ for 30-45 minutes)
Number of subjects: 21
Study 10962122 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiography (ECG)
Number of subjects: 301
Study 9192551 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 protocol (oral care instructions at 1 week before radiotherapy)
Number of subjects: 30
Study 9192551 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral care instructions)
Number of subjects: 30
Study 9192551 — intervention group
Group type: EXPERIMENTAL
Intervention: E1 protocol (oral care instructions at 1 day before radiotherapy)
Number of subjects: 30
Study 8237937 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon (alfa-2b, 10 million units three times weekly)
Number of subjects: 47
Study 8237937 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 47
Study 8237937 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon
Number of subjects: 47
Study 4035073 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course of cyclophosphamide IV 5 mg/kg daily for 6 days immediately after mastectomy
Number of subjects: 507
Study 4035073 — intervention group
Group type: COMPARATOR
Intervention: Delayed adjuvant course of cyclophosphamide IV 5 mg/kg daily for 6 days given 2-4 weeks after mastectomy
Number of subjects: 507
Study 4035073 — intervention group
Group type: EXPERIMENTAL
Intervention: Short multidrug course immediately after mastectomy followed by IV CMF for 1 year for axillary node-positive cases
Number of subjects: 507
Study 4035073 — intervention group
Group type: COMPARATOR
Intervention: Prolonged treatment with IV CMF for 1 year
Number of subjects: 507
Study 30366156 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-CE (high-definition colonoscopy with 0.4% indigo carmine panchromoendoscopy)
Number of subjects: 86
Study 30366156 — intervention group
Group type: COMPARATOR
Intervention: HD-WLE (high-definition white-light endoscopy)
Number of subjects: 86
Study 30366156 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-CE
Number of subjects: 86
Study 30366156 — intervention group
Group type: COMPARATOR
Intervention: HD-WLE
Number of subjects: 86
Study 28074489 — intervention group
Group type: EXPERIMENTAL
Intervention: Edasalonexent (6000 mg)
Number of subjects: 104
Study 28074489 — intervention group
Group type: EXPERIMENTAL
Intervention: Edasalonexent (single dose)
Number of subjects: 104
Study 28074489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 28074489 — intervention group
Group type: EXPERIMENTAL
Intervention: Edasalonexent
Number of subjects: 104
Study 27178707 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-based intervention conditions (varied by content and format)
Number of subjects: 2918
Study 27178707 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemplars within risk-based interventions
Number of subjects: 2918
Study 27178707 — intervention group
Group type: EXPERIMENTAL
Intervention: All risk-based interventions
Number of subjects: 2918
Study 24926999 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based voluntary mobile counseling and testing (CBVCT) intervention
Number of subjects: 43292
Study 24926999 — intervention group
Group type: COMPARATOR
Intervention: Standard voluntary counseling and testing (SVCT)
Number of subjects: 43292
Study 22951697 — intervention group
Group type: EXPERIMENTAL
Intervention: Candibiotic
Number of subjects: 80
Study 19403504 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (2.5‐10 microg/kg per minute) or Epinephrine (0.125‐0.5 microg/kg per minute)
Number of subjects: 130
Study 19403504 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cardiovascular support)
Number of subjects: 130
Study 17501979 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone grafts (ABG)
Number of subjects: 17
Study 17501979 — intervention group
Group type: COMPARATOR
Intervention: Distraction osteogenesis (DO)
Number of subjects: 17
Study 15065950 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisconsin Inventory of Smoking Dependence Motives (WISDM-68)
Number of subjects: 775
Study 11595068 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (isoniazid, rifampicin, ethambutol for 2 months, followed by isoniazid and rifampicin for 7 months)
Number of subjects: 31
Study 11595068 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (isoniazid, pyrazinamide, ethambutol, and ofloxacin for 2 months, followed by isoniazid, ethambutol, and ofloxacin for 10 months)
Number of subjects: 31
Study 9643160 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg
Number of subjects: 23
Study 9643160 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 6 mg
Number of subjects: 23
Study 9643160 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg or 6 mg with Hydrochlorothiazide 25 mg added
Number of subjects: 23
Study 8133729 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Bruce protocol
Number of subjects: 32
Study 8133729 — intervention group
Group type: COMPARATOR
Intervention: Modified Bruce protocol
Number of subjects: 32
Study 2799743 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises (group 1)
Number of subjects: 110
Study 2799743 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometer (group 2)
Number of subjects: 110
Study 2799743 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 110
Study 2799743 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (general outcome)
Number of subjects: 110
Study 2799743 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (FRC on day 2)
Number of subjects: 110
Study 2799743 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (FRC on day 5)
Number of subjects: 110
Study 2799743 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (arterial oxygen tension on day 2)
Number of subjects: 110
Study 2799743 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (arterial oxygen tension on day 4)
Number of subjects: 110
Study 15830475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 18
Study 15830475 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 18
Study 30569637 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose NS-0200 (1.1 g leucine/0.5 g metformin/1.0 mg sildenafil)
Number of subjects: 91
Study 30569637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 28345429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 1000 mg uric acid
Number of subjects: 45
Study 28345429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 25963345 — intervention group
Group type: EXPERIMENTAL
Intervention: Avandamet
Number of subjects: 0
Study 25963345 — intervention group
Group type: COMPARATOR
Intervention: Uptitrated Metformin
Number of subjects: 0
Study 23659360 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36
Study 23659360 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 36
Study 23659360 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stimulants
Number of subjects: 36
Study 23659360 — intervention group
Group type: EXPERIMENTAL
Intervention: Shift from inferior drug to best drug
Number of subjects: 36
Study 21680859 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscope (C‐MAC®)
Number of subjects: 93
Study 21680859 — intervention group
Group type: COMPARATOR
Intervention: Conventional Macintosh blade laryngoscope
Number of subjects: 93
Study 19797474 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 446
Study 19797474 — intervention group
Group type: COMPARATOR
Intervention: N95 respirator
Number of subjects: 446
Study 16428745 — intervention group
Group type: EXPERIMENTAL
Intervention: PTL-003
Number of subjects: 40
Study 16428745 — intervention group
Group type: COMPARATOR
Intervention: PTL-002
Number of subjects: 40
Study 15325933 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 15325933 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin receptor blockers
Number of subjects: 0
Study 11511328 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (helium and oxygen mixture)
Number of subjects: 0
Study 11511328 — intervention group
Group type: COMPARATOR
Intervention: Heliox therapy
Number of subjects: 0
Study 9402845 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOP/IMVP-Dexa chemotherapy and filgrastim (self-injected at 5 micrograms/kg body weight s.c. daily, except on cytotoxic drug days)
Number of subjects: 85
Study 9402845 — intervention group
Group type: COMPARATOR
Intervention: CEOP/IMVP-Dexa chemotherapy alone
Number of subjects: 85
Study 7687509 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant foods (foods eliciting positive skin-prick tests and positive oral challenges)
Number of subjects: 6
Study 7687509 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-relevant foods (foods eliciting positive skin tests but negative oral challenges)
Number of subjects: 6
Study 3323262 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine (up to 100 mg twice daily)
Number of subjects: 34
Study 3323262 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (up to 100 mg twice daily)
Number of subjects: 34
Study 30415890 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral inosine treatment
Number of subjects: 0
Study 30415890 — intervention group
Group type: COMPARATOR
Intervention: Genetically engineered mice (UOx gKO, cKO, Tg)
Number of subjects: 0
Study 27400949 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSCs)
Number of subjects: 0
Study 27400949 — intervention group
Group type: COMPARATOR
Intervention: Non-MSCs control group
Number of subjects: 0
Study 24314813 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-fitted compression garments
Number of subjects: 0
Study 24314813 — intervention group
Group type: COMPARATOR
Intervention: Conventional shorts (control)
Number of subjects: 0
Study 24314813 — intervention group
Group type: EXPERIMENTAL
Intervention: Loose-fitted compression garment
Number of subjects: 0
Study 24314813 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes open condition
Number of subjects: 0
Study 24314813 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes closed condition
Number of subjects: 0
Study 22748821 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg)
Number of subjects: 1552
Study 22748821 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (1-4 mg)
Number of subjects: 1552
Study 22748821 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 1552
Study 22748821 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1552
Study 20499017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulinotherapy
Number of subjects: 50
Study 20499017 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulinotherapy
Number of subjects: 50
Study 18246290 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary 2 Program (Tier 1 Program)
Number of subjects: 0
Study 15699297 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based continuing care (TEL)
Number of subjects: 359
Study 15699297 — intervention group
Group type: COMPARATOR
Intervention: Relapse prevention (RP)
Number of subjects: 359
Study 15699297 — intervention group
Group type: COMPARATOR
Intervention: Standard group counseling (STND)
Number of subjects: 359
Study 14514402 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabrasion (A group)
Number of subjects: 50
Study 14514402 — intervention group
Group type: COMPARATOR
Intervention: Conventional tangential excision (B group)
Number of subjects: 50
Study 11022057 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for atherosclerosis (hypertension, dyslipidemia, diabetes mellitus, smoking)
Number of subjects: 117
Study 11022057 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (age- and sex-matched)
Number of subjects: 117
Study 8998023 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced professional practice model
Number of subjects: 0
Study 8998023 — intervention group
Group type: EXPERIMENTAL
Intervention: One unit's cost savings
Number of subjects: 0
Study 1379576 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 216
Study 1379576 — intervention group
Group type: COMPARATOR
Intervention: Dextran-70
Number of subjects: 216
Study 6660435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal verapamil, 1 mg
Number of subjects: 26
Study 6660435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31964164 — intervention group
Group type: EXPERIMENTAL
Intervention: Case manager-assisted rehabilitation
Number of subjects: 82
Study 31964164 — intervention group
Group type: COMPARATOR
Intervention: Usual physical rehabilitation
Number of subjects: 82
Study 31725644 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaihu-Shugan-San (CHSGS) capsule
Number of subjects: 135
Study 31725644 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil oral pharmacotherapy
Number of subjects: 135
Study 31725644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 31725644 — intervention group
Group type: EXPERIMENTAL
Intervention: CHSGS capsule
Number of subjects: 135
Study 28735699 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (sertraline)
Number of subjects: 438
Study 28735699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (Coping Cat)
Number of subjects: 438
Study 28735699 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of medication and cognitive-behavioral therapy
Number of subjects: 438
Study 28735699 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 438
Study 28735699 — intervention group
Group type: EXPERIMENTAL
Intervention: SCARED-Parent
Number of subjects: 438
Study 28735699 — intervention group
Group type: EXPERIMENTAL
Intervention: SCARED-Youth
Number of subjects: 438
Study 28735699 — intervention group
Group type: EXPERIMENTAL
Intervention: SCARED-Parent (children)
Number of subjects: 438
Study 28735699 — intervention group
Group type: EXPERIMENTAL
Intervention: SCARED-Parent (adolescents)
Number of subjects: 438
Study 26003022 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Balloon (PEB)
Number of subjects: 402
Study 23132203 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Pathways (CPs)
Number of subjects: 581
Study 23132203 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 581
Study 21645330 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent pharmacological management protocol for delirium (PMD) including low-dose haloperidol at 0.5-1 mg for 7 days
Number of subjects: 428
Study 21645330 — intervention group
Group type: COMPARATOR
Intervention: No change in usual ICU care
Number of subjects: 428
Study 19958132 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese‐style active acupuncture
Number of subjects: 14
Study 19958132 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 14
Study 17082828 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDLINE-first (protocol A)
Number of subjects: 32
Study 17082828 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDLINE-last (protocol B)
Number of subjects: 32
Study 17082828 — intervention group
Group type: COMPARATOR
Intervention: Both protocols
Number of subjects: 32
Study 11815505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea + insulin
Number of subjects: 826
Study 11815505 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 826
Study 10408585 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (E = 50 min @ 50% VO2 max)
Number of subjects: 46
Study 10408585 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control day (C)
Number of subjects: 46
Study 7575256 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin solution
Number of subjects: 248
Study 7575256 — intervention group
Group type: COMPARATOR
Intervention: Fortified antibiotics (1.5% tobramycin and 10.0% cefazolin solutions)
Number of subjects: 248
Study 2248109 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic exposure to drug-related cues
Number of subjects: 0
Study 2248109 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for drug dependence
Number of subjects: 0
Study 7352840 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 57
Study 7352840 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheneizine sulfate
Number of subjects: 57
Study 7352840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 6305670 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine (150 mg bid)
Number of subjects: 6
Study 31389755 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of implants (n = 10)
Number of subjects: 20
Study 31389755 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading of implants (n = 10)
Number of subjects: 20
Study 29401297 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down treatment
Number of subjects: 119
Study 29401297 — intervention group
Group type: COMPARATOR
Intervention: Step-up treatment
Number of subjects: 119
Study 27762512 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (0.5-3 mg/h)
Number of subjects: 41
Study 27762512 — intervention group
Group type: COMPARATOR
Intervention: Terlipressin (0.5-2 mg/6h)
Number of subjects: 41
Study 24907142 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine/rilpivirine
Number of subjects: 32
Study 22314064 — intervention group
Group type: EXPERIMENTAL
Intervention: Study scrubs
Number of subjects: 30
Study 22314064 — intervention group
Group type: COMPARATOR
Intervention: Control scrubs
Number of subjects: 30
Study 21294404 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg simvastatin in the morning
Number of subjects: 52
Study 21294404 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the evening
Number of subjects: 52
Study 21294404 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening simvastatin administration
Number of subjects: 52
Study 17506592 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronic acid 800 mg plus elemental calcium 500 mg and 400 IU of vitamin D daily
Number of subjects: 79
Study 17506592 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D only (Control)
Number of subjects: 79
Study 15767608 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based balance-training program using a wobble board for 6 weeks (daily) and 6 months (weekly)
Number of subjects: 127
Study 15767608 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based balance-training program using a wobble board
Number of subjects: 127
Study 15767608 — intervention group
Group type: COMPARATOR
Intervention: Control group (testing only)
Number of subjects: 127
Study 12093429 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol ester (PSE) spread, 2 g daily for 4 weeks
Number of subjects: 105
Study 12093429 — intervention group
Group type: COMPARATOR
Intervention: Plant stanol ester (PSE) spread, 3 g daily
Number of subjects: 105
Study 10601920 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 microg/d estradiol vaginal ring
Number of subjects: 35
Study 10601920 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 microg/d estradiol vaginal ring
Number of subjects: 35
Study 7477146 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus antihypertensive medication
Number of subjects: 46